Michael Henderson - Oct 2, 2024 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Signature
/s/ Matthew Batters, as attorney-in-fact for Michael Henderson
Stock symbol
APGE
Transactions as of
Oct 2, 2024
Transactions value $
-$2,249,307
Form type
4
Date filed
10/4/2024, 08:01 PM
Previous filing
Sep 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APGE Common Stock Sale -$1.7M -30.3K -2.17% $56.07 1.36M Oct 2, 2024 Direct F1, F2
transaction APGE Common Stock Sale -$551K -9.71K -0.71% $56.74 1.35M Oct 2, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.
F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.51 to $56.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.52 to $57.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.